Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Harbaum, L; Pollheimer, MJ; Bauernhofer, T; Kornprat, P; Lindtner, RA; Schlemmer, A; Rehak, P; Langner, C.
Clinicopathological significance of prolactin receptor expression in colorectal carcinoma and corresponding metastases.
Mod Pathol. 2010; 23(7):961-971
Doi: 10.1038/modpathol.2010.83
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Langner Cord
- Co-Autor*innen der Med Uni Graz
- Bauernhofer Thomas
- Kornprat Peter
- Pollheimer Marion
- Rehak Peter
- Schlemmer Andrea
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The role of human prolactin and its receptor, the prolactin receptor, in colorectal cancer is largely unknown. Our study aimed to assess the prevalence of prolactin receptor expression, its association with clinicopathological variables, as well as its prognostic value, comparing results of primary tissues with those of corresponding metastases. In all, 373 primary colorectal cancer and 171 corresponding metastases were evaluated for prolactin receptor expression by immunohistochemistry using a tissue microarray technique. Immunoreactivity was semiquantitatively scored as either focal (<10% of tumor cells positive), moderate (10-50%), or extensive (>50%). Prolactin receptor expression was related to clinicopathological parameters as well as patient outcome. To substantiate our findings, prolactin receptor expression was additionally assessed in HT-29 and SW-480 colorectal cancer cell lines using western blot. Prolactin receptor expression was observed in 360 out of 373 (97%) primary tumors, with 21 (6%) cases showing focal, 55 (15%) moderate, and 284 (76%) extensive expression, respectively. Extensive prolactin receptor expression was significantly associated with tumor size (P=0.002) and grade (P<0.001) as well as histological subtype (P<0.001). Somer's D coefficients for concordance of primary tumors with corresponding lymph node and distant metastases were D=0.719 (P<0.001) and D=0.535 (P=0.001), respectively. Extensive prolactin receptor expression was significantly associated with disease progression (P=0.03) and cancer-specific survival (P=0.04) in patients with high-grade cancers. In conclusion, prolactin receptor expression is common in colorectal cancer, with high concordance between primary tumors and corresponding metastases. In view of evolving targeted therapy concepts in colorectal cancer, widespread prolactin receptor expression may offer a therapeutic perspective in affected patients.
- Find related publications in this database (using NLM MeSH Indexing)
- Adenocarcinoma - metabolism Adenocarcinoma - mortality Adenocarcinoma - pathology
- Adult -
- Aged -
- Aged, 80 and over -
- Blotting, Western -
- Colorectal Neoplasms - metabolism Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology
- Disease-Free Survival -
- Female -
- Gene Expression -
- Gene Expression Profiling -
- Humans -
- Immunohistochemistry -
- Kaplan-Meier Estimate -
- Male -
- Middle Aged -
- Neoplasm Metastasis - pathology
- Neoplasm Staging -
- Prognosis -
- Receptors, Prolactin - biosynthesis
- Tissue Array Analysis -
- Find related publications in this database (Keywords)
- colorectal cancer
- prolactin receptor
- immunohistochemistry
- cell line
- survival
- clinical significance
- targeted therapy